MRTX1133, a potent, selective, and non-covalent KRASG12D inhibitor, exhibited a dose-dependent inhibition of KRAS-mediated signal transduction and marked tumor regression (≥30%) in a subset of KRASG12D-mutant cell line-derived and patient-derived xenograft models, including 8/11 (73%) PDAC models [69]. This evidence concerns the gene KRAS and neoplasm.